Risks in new drug development: Approval success rates for investigational drugs

被引：298
作者：
DiMasi, JA [1 ]
机构：
[1] Tufts Univ, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 05期
关键词：
D O I：
10.1067/mcp.2001.115446
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：297 / 307
页数：11
相关论文
共 24 条
  • [1] BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS - CLINICAL SUCCESS RATES
    BIENZTADMOR, B
    DICERBO, PA
    TADMOR, G
    LASAGNA, L
    [J]. BIO-TECHNOLOGY, 1992, 10 (05): : 521 - 525
  • [2] COX C, 1978, UNPUB TECHNOLOGICAL
  • [3] Cox D. R., 1984, ANAL SURVIVAL DATA
  • [4] RESEARCH-AND-DEVELOPMENT COSTS FOR NEW DRUGS BY THERAPEUTIC CATEGORY - A STUDY OF THE UNITED-STATES PHARMACEUTICAL-INDUSTRY
    DIMASI, JA
    HANSEN, RW
    GRABOWSKI, HG
    LASAGNA, L
    [J]. PHARMACOECONOMICS, 1995, 7 (02) : 152 - 169
  • [5] NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992
    DIMASI, JA
    SEIBRING, MA
    LASAGNA, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (06) : 609 - 622
  • [6] SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES
    DIMASI, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) : 1 - 14
  • [7] COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY
    DIMASI, JA
    HANSEN, RW
    GRABOWSKI, HG
    LASAGNA, L
    [J]. JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) : 107 - 142
  • [8] NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1990
    DIMASI, JA
    BRYANT, NR
    LASAGNA, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) : 471 - 486
  • [9] DiMasi JA, 2000, DRUG INF J, V34, P1169, DOI 10.1177/009286150003400425
  • [10] DiMasi JA., 1995, INT J ECON BUS, V2, P201, DOI [10.1080/758519309, DOI 10.1080/758519309]
123